Corbus Pharmaceuticals Strengthens Balance Sheet with up to $121 Million in New Capital
29 juil. 2020 08h05 HE
|
Corbus Pharmaceuticals Holdings, Inc.
Aggregate of $71 million of ATM proceeds executed at weighted average price of $7.70 per shareReceived $20 million first tranche from $50 million debt facility with K2 HealthVentures Cash on hand of...
Corbus Pharmaceuticals Appoints George Golumbeski, Ph.D., to Board of Directors
08 juil. 2020 08h05 HE
|
Corbus Pharmaceuticals Holdings, Inc.
Dr. Golumbeski formerly led corporate and business development at Celgene and NovartisAppointment adds unique skill set to Corbus Board ahead of several key data readouts this summer Norwood, MA,...
Corbus Pharmaceuticals Presents Data Demonstrating ACR CRISS Score Reflects Patient-Reported Outcomes at 6th Systemic Sclerosis World E-Congress
29 juin 2020 08h05 HE
|
Corbus Pharmaceuticals Holdings, Inc.
Phase 2 systemic sclerosis (SSc) analyses show ACR CRISS score correlates with improvements from baseline in how patients feel and function through two years in the lenabasum Phase 2 open-label...
Corbus Pharmaceuticals Reports Last Subject Visit in Phase 2b Study of Lenabasum for Treatment of Cystic Fibrosis
22 juin 2020 08h05 HE
|
Corbus Pharmaceuticals Holdings, Inc.
Topline data on schedule for Q3 2020Reduction in pulmonary exacerbations (PEx) as primary endpoint Study enrolled 426 participants regardless of CFTR mutation or background CFTR-targeting...
Corbus Pharmaceuticals Announces Publication of Phase 2b Cystic Fibrosis Study Patient Demographics and Baseline Disease Characteristics in the Journal of Cystic Fibrosis
01 juin 2020 08h05 HE
|
Corbus Pharmaceuticals Holdings, Inc.
Phase 2b study of lenabasum for treatment of cystic fibrosis enriched for patients at high risk of pulmonary exacerbationsStudy on target for data readout in late summer 2020 Norwood, MA, June ...
Corbus Pharmaceuticals Reports Last Subject Visit in RESOLVE-1 Phase 3 Study of Lenabasum for Treatment of Systemic Sclerosis
27 mai 2020 08h05 HE
|
Corbus Pharmaceuticals Holdings, Inc.
Topline data on schedule for summer 2020Systemic sclerosis (SSc) is a rare, serious and life-threatening autoimmune disease affecting ~200,000 people in the U.S., EU and JapanThere are no FDA-approved...
Corbus Pharmaceuticals Announces Publication of Two Abstracts at EULAR 2020 E-Congress
22 mai 2020 08h05 HE
|
Corbus Pharmaceuticals Holdings, Inc.
First abstract highlights pre-clinical data linking lenabasum’s mechanism of action to inhibiting inflammasome activationSecond abstract outlines baseline characteristics of RESOLVE-1 patients in EU ...
Corbus Pharmaceuticals to Present at Two Upcoming Investor Conferences
15 mai 2020 08h05 HE
|
Corbus Pharmaceuticals Holdings, Inc.
Norwood, MA, May 15, 2020 (GLOBE NEWSWIRE) -- Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP) (“Corbus” or the “Company”), a clinical-stage drug development company pioneering transformative...
Corbus Pharmaceuticals Reports First Quarter Financial Results and Corporate Updates
11 mai 2020 07h05 HE
|
Corbus Pharmaceuticals Holdings, Inc.
Topline results for lenabasum Phase 3 RESOLVE-1 study in systemic sclerosis remain on schedule for summer of 2020, followed by Phase 2b study data in cystic fibrosis Phase 1 trial of CRB-4001 remains...
Corbus Pharmaceuticals to Report First Quarter Results on May 11, 2020
04 mai 2020 08h05 HE
|
Corbus Pharmaceuticals Holdings, Inc.
- Management to host conference call and webcast on Monday, May 11 at 8:30 a.m. ET- NORWOOD, MA, May 04, 2020 (GLOBE NEWSWIRE) -- Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP) (“Corbus” or...